189 related articles for article (PubMed ID: 36413797)
21. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
Lee JH; Kim HJ; Kim YH
J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
[TBL] [Abstract][Full Text] [Related]
22. Comparative Treatment Failure Rates of Respiratory Fluoroquinolones or β-Lactam + Macrolide Versus β-Lactam Alone in the Treatment for Community-Acquired Pneumonia in Adult Outpatients: An Analysis of a Nationally Representative Claims Database.
Lee MG; Lee SH; Chang SS; Chan YL; Pang L; Hsu SM; Lee CC
Medicine (Baltimore); 2015 Sep; 94(39):e1662. PubMed ID: 26426664
[TBL] [Abstract][Full Text] [Related]
23. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
[TBL] [Abstract][Full Text] [Related]
24. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM
J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448
[TBL] [Abstract][Full Text] [Related]
25. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
[TBL] [Abstract][Full Text] [Related]
26. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
Kyriazopoulou E; Sinapidis D; Halvatzis S; Velissaris D; Alexiou N; Kosmas V; Adami ME; Kyprianou M; Kyprianou A; Stefos A; Lada M; Koutoukas P; Pavlaki M; Kyriakoudi A; Makina A; Gogos C; Niederman MS; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2020 Jan; 55(1):105836. PubMed ID: 31704213
[TBL] [Abstract][Full Text] [Related]
27. Elderly patients with community-acquired pneumonia: optimal treatment strategies.
Thiem U; Heppner HJ; Pientka L
Drugs Aging; 2011 Jul; 28(7):519-37. PubMed ID: 21721597
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
[TBL] [Abstract][Full Text] [Related]
29. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
30. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
[TBL] [Abstract][Full Text] [Related]
31. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
32. Doxycycline vs. macrolides in combination with a β-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients.
Aldhahri RK; Gabb SG; Shoaib OA; Almadani RM; Eljaaly K; Thabit AK
Eur J Med Res; 2022 Dec; 27(1):279. PubMed ID: 36482485
[TBL] [Abstract][Full Text] [Related]
33. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
34. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis.
Ito A; Ishida T; Tachibana H; Tokumasu H; Yamazaki A; Washio Y
Sci Rep; 2019 Dec; 9(1):18406. PubMed ID: 31804572
[TBL] [Abstract][Full Text] [Related]
35. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis.
Horita N; Otsuka T; Haranaga S; Namkoong H; Miki M; Miyashita N; Higa F; Takahashi H; Yoshida M; Kohno S; Kaneko T
Respirology; 2016 Oct; 21(7):1193-200. PubMed ID: 27338144
[TBL] [Abstract][Full Text] [Related]
36. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
37. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
Ruhe J; Mildvan D
Infect Dis Clin North Am; 2013 Mar; 27(1):115-32. PubMed ID: 23398869
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia.
Hopkins TM; Juang P; Weaver K; Kollef MH; Betthauser KD
Clin Ther; 2019 Dec; 41(12):2540-2548. PubMed ID: 31676040
[TBL] [Abstract][Full Text] [Related]
39. Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination.
Karhu J; Ala-Kokko TI; Ohtonen P; Syrjälä H
Acta Anaesthesiol Scand; 2013 May; 57(5):587-93. PubMed ID: 23379766
[TBL] [Abstract][Full Text] [Related]
40. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
